Keyword Analysis & Research: ruxolitinib ifn


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
ruxolitinib ifn1.230.381355915
ruxolitinib1.820.419789811
ifn1.361217163

Keyword Research: People who searched ruxolitinib ifn also searched

Keyword CPC PCC Volume Score
ruxolitinib infection0.781643532
ruxolitinib in tiruvallur1.910.88885
ruxolitinib incyte1.720.842128
ruxolitinib indication0.721479664
ruxolitinib incb0184240.040.2682277
ruxolitinib in adivaragapuram1.010.764798
ruxolitinib in 6000640.410.7733148
ruxolitinib in 6001000.270.9564583
ruxolitinib in gvhd1.440.8600156
ruxolitinib in 6000190.40.4581819
ruxolitinib in 6000371.050.5867296
ruxolitinib in 6000490.010.7611664
ruxolitinib in 6000500.460.9611172
ruxolitinib in 6000551.550.4268140
ruxolitinib injection0.540.1343923
ruxolitinib and infection1.650.6257911

Search Results related to ruxolitinib ifn on Search Engine

  • Treatment with a JAK1/2 inhibitor ameliorates murine ... - Nature

    nature.com

    https://www.nature.com/articles/s41423-022-00904-y

    DA: 26 PA: 14 MOZ Rank: 58

  • Treatment with a JAK1/2 inhibitor ameliorates murine ... - Nature

    nature.com

    https://www.nature.com/articles/s41423-022-00904-y

    DA: 39 PA: 53 MOZ Rank: 70

  • Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized …

    ashpublications.org

    https://ashpublications.org/blood/article/140/Supplement%201/577/488443/Final-Results-of-Ruxopeg-a-Phase-1-2-Adaptive

    WEBNov 15, 2022 · IFNa can reduce mutant allele burden and fibrosis but is poorly tolerated in highly symptomatic patients (pts). The RUXOPEG study was designed to assess the …

    DA: 6 PA: 98 MOZ Rank: 83

  • Ruxolitinib and interferon-α2 combination therapy for

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/33054051/

    WEBSep 1, 2020 · PMID: 33054051. PMCID: PMC7556624. DOI: 10.3324/haematol.2019.235648. Abstract. We report the final 2-year end-of-study results … Author: Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykke... Publish Year: 2020

    Author: Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykke...

    Publish Year: 2020

    DA: 93 PA: 50 MOZ Rank: 89

  • Treatment with a JAK1/2 inhibitor ameliorates murine

    nature.com

    https://www.nature.com/articles/s41423-022-00904-y

    WEBAug 30, 2022 · Functionally, ruxolitinib inhibited the secretion of the proinflammatory cytokines IFNγ and TNF from splenic CD4 + T cells. Additionally, ruxolitinib treatment …

    DA: 72 PA: 23 MOZ Rank: 78


  • Ruxolitinib and interferon-α2 combination therapy for …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556624/

    WEBSep 9, 2020 · We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon …

    DA: 53 PA: 63 MOZ Rank: 60

  • Distinct effects of ruxolitinib and interferon-alpha on …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221569/

    WEBWe investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and interferon-alpha (IFN-α), on the disease-initiating HSC population. Whereas ruxolitinib …

    DA: 94 PA: 73 MOZ Rank: 73

  • Combined IFN-γ and JAK inhibition to treat …

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S0091674922010557

    WEBJan 1, 2023 · Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor 27 that is approved for the treatment of myelofibrosis 28 and polycythemia vera, 29 is efficacious in numerous …

    DA: 80 PA: 18 MOZ Rank: 64

  • Distinct effects of ruxolitinib and interferon-alpha on …

    nature.com

    https://www.nature.com/articles/s41375-019-0638-y

    WEBPublished: 15 November 2019. Chronic myeloproliferative neoplasms. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm …

    DA: 37 PA: 74 MOZ Rank: 79

  • Mechanisms Underlying the Anti-inflammatory and …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854013/

    WEBNov 7, 2019 · Ruxolitinib impairs cytokine expression by inhibiting LPS/TLR4/IFN beta signaling pathway. Cytokine repression contributes to the anti-inflammatory effect of …

    DA: 57 PA: 69 MOZ Rank: 25